Cadila Healthcare Q4 PAT surges 73% yoy; US formulations business revenue at Rs1,509cr
EBIDTA grew by 8% on a yoy basis to Rs855cr during the fourth quarter
May 27, 2021 5:09 IST India Infoline News Service
Total Income from operations of Rs3,847cr, for the fourth quarter, up by 3% on a yoy basis from Rs3,752cr registered during the corresponding period of the previous year.
Earnings before Interest, Depreciation and Tax (EBIDTA) grew by 8% on a yoy basis to Rs855cr during the fourth quarter.
Cadila Healthcare Ltd ended at Rs626.70 down by Rs1.2 or 0.19% from its previous closing of Rs627.90 on the BSE.
The Company’s business in India geography which comprises Human health formulations business, Consumer wellness business and Animal health business posted a strong growth during the quarter as it grew by 18% on a y-o-y basis and registered revenues of Rs1,772cr. Human health formulations business in India grew by 15% and Consumer wellness business grew by 22% on a yoy basis during the quarter.
US formulations business registered revenues of Rs1,509cr during the quarter. Strengthening its regulatory pipeline, the Company filed 22 additional ANDAs during the year with the USFDA, taking the cumulative filings to 412. The Company received 35 ANDAs approvals during the year, taking the total to 317 product approvals.
Get Access to Stock Reports+ and Customised Investment Ideas
